Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studies.
Narazaki
Masashi
M
Tosato
Giovanna
G
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D042783:Endothelial Cells / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D009336:Necrosis; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D019010:Vascular Cell Adhesion Molecule-1 / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; D019010:Vascular Cell Adhesion Molecule-1; D000068258:Bevacizumab